Practice-Changing Research on Prostate Cancer Presented at ASCO 2012: With Commentary by Dr Neal Shore
This article reviews the most significant research on prostate cancer presented last month at ASCO 2012, with commentary from Dr Neal Shore.
Initial salvage treatment with allogenic stem cell transplant (ASCT) is feasible and yields superior outcomes to salvage chemotherapy in acute myeloid leukemia (AML) patients.
Abiraterone acetate (AA) plus prednisone (P) produced a statistically significant improvement in radiographic progression-free survival (rPFS) and a strong trend for increased overall survival (OS), according to the results of a study presented by a multinational team of researchers at the 2012 American Society of Clinical Oncology Annual Meeting.
Dr. Barbara Burtness is a physician-scientist of the Fox Chase Cancer Center and an expert in the treatment of head and neck cancer.
Maintenance Gemcitabine plus Paclitaxel Chemotherapy Offers Improved Outcomes in Metastatic Breast Cancer
Maintenance chemotherapy with the combination of gemcitabine and paclitaxel (GP) following clinical response to GP is associated with improved survival times.
Neither weekly nab-paclitaxel nor ixabepilone are superior to weekly paclitaxel in patients with chemotherapy-naïve advanced breast cancer receiving bevacizumab.
ASCO: Duloxetine is Effective and Well-Tolerated for Treatment of Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Daily duloxetine therapy effective and well-tolerated for the treatment of CIPN.
ASCO: Radium-223 Prolongs Survival Time for Patients with Bone-Metastatic Castration-Resistant Prostate Cancer
Radium-223 chloride therapy significantly prolongs median OS time for men with castration-resistant prostate cancer (CRPC) bone metastasis.
Weekly Paclitaxel After Adjuvant FAC Modestly Improves DFS in High-Risk, Node-Negative Breast CA Patients
Adding weekly paclitaxel to adjuvant FAC therapy offers a modest improvement in disease-free survival for patients with high-risk, node-negative breast cancer.
Crizotinib has a strong response rate, progression-free survival (PFS), and is well tolerated in patients with ALK-positive non-small cell lung cancer (NSCLC).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immunotherapy and the Future of Prostate Cancer Treatment
- Explaining Androgen Receptor-indifferent Prostate Cancer
- Dual Immunotherapy Active vs Sunitinib for PD-L1+ Advanced RCC
- 2017 ASCO GU Symposium: Updates in Managing Small Renal Masses
- First-line Immune Checkpoint Inhibition Cost-effective in Melanoma